Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $15.66 million.

"We are entering 2020 with a clear plan to drive shareholder value for Rigel," said Raul Rodriguez, Rigel's president and CEO. "We see substantial opportunities for TAVALISSE to meet patient needs in the growing adult chronic ITP market, particularly as an early line therapy. Utilization in these less refractory patients continues to grow with the support of ongoing physician education and data generation. To expand the range of TAVALISSE indications, we are conducting a Phase 3 trial in warm AIHA and expect to complete patient enrollment midyear. In addition, we are extremely excited about the potential of our early stage candidates and are currently exploring partnership opportunities that would enable Rigel to realize near-term value while also participating meaningfully in the upside of these programs."

For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.